Jakarta, April 30, 2026 – Based on the Consolidated Financial Statements of PT Enseval Putera Megatrading Tbk and its Subsidiaries (the “Company”) as of March 31, 2026 and for the period then ended (Unaudited), the Company hereby reports that in the first quarter of 2026, the Company recorded Net Sales of IDR 9,057.13 billion, representing an increase of 9.02% compared to Net Sales in the first quarter of 2025 of IDR 8,307.89 billion.

The Company’s Net Sales reached IDR 9,057.13 billion, growing by 9.02% compared to the first quarter of 2025 of IDR 8,307.89 billion, reflecting sustained business growth.

In line with the increase in business volume, Cost of Goods Sold amounted to IDR 8,158.15 billion, up by 9.74% compared to the same period in the previous year. Accordingly, the Company recorded Gross Profit of IDR 898.98 billion, growing by 2.86% compared to Gross Profit in the first quarter of 2025.

In the first quarter of 2026, Operating Expenses amounted to IDR 561.71 billion, consisting of Selling Expenses of IDR 501.10 billion and General and Administrative Expenses of IDR 60.61 billion, increasing by 9.05% compared to the same period in the previous year, in line with the Company’s expansion and operational strengthening. The Company recorded Operating Profit of IDR 337.26 billion.

Profit Before Income Tax was recorded at IDR 346.29 billion. The composition of Other Income (Expenses) includes finance income of IDR 2.34 billion, finance costs of IDR 5.43 billion, final tax expense of IDR 0.74 billion, share of net profit of associates of IDR 1.63 billion, other operating income of IDR 18.16 billion, and other operating expenses of IDR 6.93 billion.

Income Tax Expense amounted to IDR 77.34 billion, relatively stable compared to the same period in the previous year of IDR 77.12 billion.

Accordingly, the Company recorded Profit for the Period of IDR 268.95 billion in the first quarter of 2026, reflecting maintained performance amid operational dynamics and business growth.

Based on the comparison between the Company’s Consolidated Statement of Financial Position as of March 31, 2026 (Unaudited) and December 31, 2025 (Audited), Total Assets increased by 7.41% from IDR 13.13 trillion to IDR 14.11 trillion. Total Liabilities increased by 13.36% from IDR 5.27 trillion as of December 31, 2025 to IDR 5.97 trillion in the first quarter of 2026. As a result, Total Equity increased by 3.42% from IDR 7.87 trillion to IDR 8.14 trillion in the first quarter of 2026.

Performance of Each Division
The Company currently has 7 divisions, consisting of Consumer Goods, Prescription Pharmaceuticals, Over-the-Counter (OTC) Pharmaceuticals, Raw Materials for Sale, Medical Equipment, Healthcare Services and Logistics, as well as Veterinary and Livestock Products.

The performance details of each division are as follows:   

• The Consumer Goods Division contributed the largest share to total Net Sales at 38.26%. In the first quarter of 2026, this division recorded Net Sales of IDR 3,465.48 billion, an increase of 11.36% compared to the same period in 2025.
• The Prescription Pharmaceuticals Division contributed the second largest share at 34.42%. Up to the first quarter of 2026, this division recorded Net Sales of IDR 3,117.37 billion, growing by 10.40% compared to the same period in 2025.
• The Over-the-Counter (OTC) Pharmaceuticals Division recorded Net Sales of IDR 1,318.95 billion in the first quarter of 2026, contributing 14.56% and increasing by 1.82% compared to the same period in 2025.
• The Raw Materials Division recorded Net Sales of IDR 663.04 billion in the first quarter of 2026, increasing by 8.48% compared to the same period in 2025, contributing 7.32%.
• The Medical Equipment Division contributed 4.97% in the first quarter of 2026, with Net Sales of IDR 450.41 billion, increasing by 4.49% compared to the same period in 2025.
• Net Sales from the Healthcare Services and Logistics Division amounted to IDR 30.02 billion, increasing by 49.55% compared to the same period in 2025, contributing 0.33%.
• Net Sales from the Veterinary and Livestock Products Division amounted to IDR 11.86 billion, decreasing by 19.51% compared to the same period in 2025 of IDR 14.73 billion, contributing 0.13% to total Net Sales.

About Enseval
Enseval is the largest distribution company in Indonesia, having started its distribution activities in 1973 and currently employing more than 4,400 employees. Enseval became a public company on August 1, 1994 under the name PT Enseval Putera Megatrading Tbk (IDX: EPMT). In addition to distributing products from the Kalbe Group, Enseval is also entrusted by other principals both domestically and internationally. The Company has an extensive distribution network with 3 Distribution Centers located in Jakarta, Cikarang, and Surabaya, and 48 branches across Indonesia, as well as 24 branches through its subsidiary PT Tri Sapta Jaya. To date, the Company has 9 subsidiaries operating in distribution and logistics, raw materials, medical equipment, healthcare services, and transportation.